Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Summary

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

Timeline

Start

2024-05-09

Primary completion

2026-12

Completion

2027-11

Drugs

Indications